L-Deprenyl does not reduce brain damage in global forebrain ischemia in adult gerbils (Meriones ungiculatus)

Journal of the Neurological Sciences

Volumn 148, Issue 1, 1997, Pages 1-5

  Ballabriga, Jordi ^a   Pellisé, Anna ^a   Ferrer, Isidre ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

gerbil; global forebrain ischemia; L deprenyl; neuroprotection

Indexed keywords

MONOAMINE OXIDASE INHIBITOR; NEUROPROTECTIVE AGENT; SELEGILINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN ISCHEMIA; CAROTID ARTERY OBSTRUCTION; CELL COUNT; CONTROLLED STUDY; HIPPOCAMPUS; HISTOLOGY; INTRAPERITONEAL DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL; PYRAMIDAL NERVE CELL;

AGE FACTORS; ANIMALS; BRAIN ISCHEMIA; CELL DEATH; GERBILLINAE; NEUROPROTECTIVE AGENTS; PROSENCEPHALON; PYRAMIDAL CELLS; REPERFUSION INJURY; SELEGILINE;

EID: 0031148573     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-510X(96)05306-3     Document Type: Article

References (31)

1. Bryson, H.M., Milne, R.J. and Chrisp, P. (1992) Selegiline. An appraisal of the basis of its pharmaeconomic and quality-of-life benefits in Parkinson's disease. Pharmakoeconomics, 2: 118-136.
2. Calne, D.B. (1992) The free radical hypothesis in idiopathic Parkinsonism: evidence against it. Ann. Neurol., 32: 799-803.
3. Carrillo, M.C., Kanai, S., Sato, Y., Ivy, G.O. and Kitani, K. (1992a) Sequential changes in activities of superoxide dismutase and catalase in brain regions and liver during L-deprenyl infusion in male rats. Biochem. Pharmacol., 44: 2185-2189.
4. Carrillo, M.C., Kanai, S., Nokubo, M., Ivy, G.O., Sato, Y. and Kitani, K. (1992b) (-)-Deprenyl increases activities of superoxide dismutase and catalase in striatum but not in hippocampus: the sex and age-related differences in the optimal dose in the rat. Exp. Neurol., 116: 286-294.
5. Ferrer, I., Tortosa, A., Macaya, A., Sierra, A., Moreno, D., Munell, F., Blanco, R. and Squier, W. (1994) Evidence of nuclear DNA fragmentation following hypoxia-ischemia in the infant rat brain, and transient forebrain ischemia in adult gerbil. Brain Pathol., 4: 115-122.
6. Heinonen, E.H. and Rinne, U.K. (1989) Selegiline in the treatment of Parkinson's disease. Acta Neurol. Scand., 80: 103-111.
7. Heinonen, E.H., Anttila, M.I. and Lamminstausta, A.S. (1994) Pharmacokinetic aspects of L-deprenyl (selegiline) and its metabolites. Clin. Pharmacol. Ther., 56: 742-749.
8. Ito, U., Spatz, M., Walker, J.T. Jr. and Klatzo, I. (1975) Experimental cerebral ischemia in Mongolian gerbils, I: light microscopic observations. Acta Neuropathol. (Berl.), 32: 209-223.
9. Johansen, F.F., Jorgensen, M.B. and Diemer, N.H. (1983) Resistance of hippocampal CA1 interneurons to 20 min of transient cerebral ischaemia in the rat. Acta Neuropathol. (Berl.)., 61: 135-140.
10. Kirino, T. (1982) Delayed neuronal death in the gerbil hippocampus following transient forebrain ischaemia. Brain Res., 239: 57-69.
11. Kirino, T. and Sano, K. (1984a) Selective vulnerability in the gerbil hippocampus following transient ischaemia. Acta Neuropathol. (Berl.), 62: 201-208.
12. Kirino, T., Tamura, A. and Sano, K. (1984b) Delayed neuronal death in the rat hippocampus after forebrain ischaemia. Acta Neuropathol. (Berl.), 64: 139-147.
13. Knoll, J. (1989) The pharmacology of selegiline ((-)-deprenyl). New aspect. Acta Neurol. Scand. 1989; 126: 83-91.
14. Knollema, S., Aukema, W., Hom, H., Korf, J. and Horst, G.J.T. (1995) L-Deprenyl reduces brain damage in rats exposed to transient hypoxia-ischemia. Stroke, 26: 1883-1887.
15. Kogure, K. and Kato, H. (1994) Neurochemistry of stroke. In: H.J.M. Barnett, J.P. Mohr, B.M. Stein and F.M. Yatsu (Eds.), Stroke: pathophysiology, diagnosis and treatment. 2nd ed. Churchill Livingstone, New York, pp. 69-103.
16. Landau, W.M. (1990) Pyramid sale in the bucket shop: DATATOP bottoms out. Neurology, 40: 1337-1339.
17. Lange, K.W., Riederer, P. and Youdim, M.B.H. (1992) Biochemical actions of L-deprenyl (selegiline). Clin. Pharmacol. Ther., 56: 734-741.
18. Mangoni, A., Grassi, M.P., Frattola, L., Piolti, R., Bassi, S., Motta, A., Marcone, A. and Smirne, S. (1991) Effects of MAO-B inhibitor in the treatment of Alzheimer's disease. Eur. Neurol., 31: 100-107.
19. Matsui, Y. and Kumagae, Y. (1991) Monoamine oxidase inhibitors prevent striatal neuronal necrosis induced by transient forebrain ischaemia. Neurosci. Lett., 126: 175-178.
20. Myllylä, V.V., Sotaniemi, K., Vuorinen, J.A. and Heinonen, E.H. (1992) Selegiline as initial treatment in de novo Parkinsonian patients. Neurology, 42: 339-343.
21. Petito, C.K. and Pulsinelli, W.A. (1984a) Delayed neuronal recovery and neuronal death in rat hippocampus following severe cerebral ischaemia: possible relationship to abnormalities in neuronal processes. J. Cereb. Blood Flow Metab., 4: 194-205.
22. Petito, C.K. and Pulsinelli, W.A. (1984b) Sequential development of reversible and irreversible neuronal damage following cerebral ischemia. J. Neuropathol. Exp. Neurol., 43: 141-153.
23. Salo, P.T. and Tatton, W.G. (1992) Deprenyl reduces the death of motoneurons caused by axotomy. J. Neurosci. Res., 31: 394-400.
24. Schmitdt-Kastner, R. and Freund, T.R. (1991) Selective vulnerability of the hippocampus in brain ischemia. Neuroscience, 40: 599-636.
25. Tariot, P.N., Sunderland, T., Weingartner, H., Murphy, D.L., Welkowitz, J.A., Thompson, K. and Cohen, R.M. (1987) Cognitive effects of L-deprenyl in Alzheimer's disease. Psychopharmacology, 91(4): 489-495.
26. Tatton, W.G. and Greenwood, C.E. (1991) Rescue of dying neurons: a new action for deprenyl in MPTP Parkinsonism. J. Neurosci. Res., 30: 666-672.
27. The Parkinson Study Group (1989) Effect of deprenyl on the progression of disability in early Parkinson's disease. N. Engl. J. Med., 321: 1364-1371.
28. Tortosa, A. and Ferrer, I. (1993) Parvalbumin immnuoreactivity of the hippocampus in brain ischaemia: a qualitative and quantitative sequential study. Neuroscience, 55: 33-43.
29. Tortosa, A., Rivera, R. and Ferrer, I. (1994) Dose-related effects of cycloheximide on delayed neuronal death in the gerbil hippocampus after bilateral transitory forebrain ischemia. J. Neurol. Sci., 121: 10-17.
30. Youdim, M.B.H. and Finberg, J.P.M. (1994) Pharmacological actions of L-deprenyl (selegiline) and other selective monoamine oxidase inhibitors. Clin. Pharmacol. Ther., 56: 725-733.
31. Wiseman, L.R. and McTavish, D. (1995) Selegiline. A review of its clinical efficacy in Parkinson's disease and its clinical potential in Alzheimer's disease. C.N.S. drugs, 4: 230-246.